Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Guus J. J. E. Heynen"'
Autor:
Guus J. J. E. Heynen, Kamil Lisek, Regina Vogel, Annika Wulf-Goldenberg, Joshua Alcaniz, Elodie Montaudon, Elisabetta Marangoni, Walter Birchmeier
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-15 (2022)
Abstract Background PI3K signaling is frequently activated in breast cancer and is targeted by PI3K inhibitors. However, resistance of tumor cells to PI3K inhibition, often mediated by activated receptor tyrosine kinases, is commonly observed and red
Externí odkaz:
https://doaj.org/article/c69ce1776048465cb6d9ef9dd5f6f21e
Autor:
Guus J. J. E. Heynen, Francis Baumgartner, Michael Heider, Upayan Patra, Maximilian Holz, Jan Braune, Melanie Kaiser, Isabell Schäffer, Stefanos A. Bamopoulos, Evelyn Ramberger, Arunima Murgai, Yuen Lam Dora Ng, Uta Margareta Demel, Dominik Laue, Sven Liebig, Josefine Krüger, Martin Janz, Axel Nogai, Markus Schick, Philipp Mertins, Stefan Müller, Florian Bassermann, Jan Krönke, Ulrich Keller, Matthias Wirth
Publikováno v:
Blood Advances
Proteasome inhibition is a highly effective treatment for multiple myeloma (MM). However, virtually all patients develop proteasome inhibitor resistance, which is associated with a poor prognosis. Hyperactive small ubiquitin-like modifier (SUMO) sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e3785fe11be986954c96a6487cb6c9
http://edoc.mdc-berlin.de/21976/2/21976suppl.zip
http://edoc.mdc-berlin.de/21976/2/21976suppl.zip
Autor:
Sander Palit, Cor Lieftink, René Bernards, Wilbert Zwart, Andreas Schlicker, Noorjahan Jagalur Basheer, Guus J. J. E. Heynen, Ekaterina Nevedomskaya, Prashanth Kumar Bajpe
Publikováno v:
Molecular Cancer Research, 14(5), 411-422. American Association for Cancer Research Inc.
Europe PubMed Central
Europe PubMed Central
Neuroblastoma cell lines can differentiate upon treatment with retinoic acid (RA), a finding that provided the basis for the clinical use of RA to treat neuroblastoma. However, resistance to RA is often observed, which limits its clinical utility. Us
Autor:
Guus J. J. E. Heynen, Wipawadee Grernrum, René Bernards, Roderick L. Beijersbergen, Iris de Rink, Sidong Huang, Prashanth Kumar Bajpe, Wouter Nijkamp, Lorenza Mittempergher
Publikováno v:
Molecular and Cellular Biology. 33:3343-3353
Retinoids play key roles in development, differentiation, and homeostasis through regulation of specific target genes by the retinoic acid receptor/retinoid X receptor (RAR/RXR) nuclear receptor complex. Corepressors and coactivators contribute to it
Autor:
Yulan Wang, Egbert F. Smit, Michael J. Seckl, Zhigang Liu, Emily Chater, Huiru Tang, Guus J. J. E. Heynen, Olivier E. Pardo, Hongde Li, William B. Stokes, Yili Hu, Julian Downward, Elza C. de Bruin, Rajat Roy
Publikováno v:
Cell discovery, 2. Nature Publishing Group
Cell Discovery
Li, H, Stokes, W, Chater, E, Roy, R, de Bruin, E, Hu, Y, Liu, Z, Smit, E F, Heynen, G J, Downward, J, Seckl, M J, Wang, Y, Tang, H & Pardo, O E 2016, ' Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer ', Cell discovery, vol. 2, pp. 16031 . https://doi.org/10.1038/celldisc.2016.31
Europe PubMed Central
Cell Discovery
Li, H, Stokes, W, Chater, E, Roy, R, de Bruin, E, Hu, Y, Liu, Z, Smit, E F, Heynen, G J, Downward, J, Seckl, M J, Wang, Y, Tang, H & Pardo, O E 2016, ' Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer ', Cell discovery, vol. 2, pp. 16031 . https://doi.org/10.1038/celldisc.2016.31
Europe PubMed Central
Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M EGFR muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3297e9686d85340d804bb4c79d1110f0
https://research.vumc.nl/en/publications/8f53a124-251f-4cf8-ab1d-e9a335e94976
https://research.vumc.nl/en/publications/8f53a124-251f-4cf8-ab1d-e9a335e94976
Autor:
Guus J. J. E. Heynen, Cor Lieftink, René Bernards, Valentina Gambino, Roderick L. Beijersbergen, Loredana Vecchione, Stefan M. Willems, Giovanni Germano, Anirudh Prahallad, Bastiaan Evers, Federica Di Nicolantonio, Alberto Bardelli
Publikováno v:
Cell Reports, Vol 12, Iss 12, Pp 1978-1985 (2015)
Cell Reports [E], 12(12), 1978. Cell Press
Cell Reports [E], 12(12), 1978. Cell Press
SummaryMost BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR. We performed an RNA-interference-based genetic scre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b2808d2b6590c5542fe90e2afb7f042
http://hdl.handle.net/2318/1558698
http://hdl.handle.net/2318/1558698
Cancer therapeutics that target a signaling pathway to which the cancer cells are addicted can deliver dramatic initial responses, but resistance is nearly always inevitable. A variety of mechanisms that cancer cells employ to escape from targeted ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::141db04efe790fe218ad6a25b8502748
https://europepmc.org/articles/PMC4615055/
https://europepmc.org/articles/PMC4615055/
Autor:
Christian U. Blank, René Bernards, Wipawadee Grernrum, Jelle Wesseling, Federica Di Nicolantonio, Andreas Schlicker, Chong Sun, Prashanth Kumar Bajpe, Stefan M. Willems, Alberto Bardelli, Sebastijan Hobor, Stéphan Vagner, Ingrid Hofland, Guus J. J. E. Heynen, Liqin Wang, Christina Mateus, John B. A. G. Haanen, Lodewyk F. A. Wessels, Davide Zecchin, Cor Lieftink, Roderick L. Beijersbergen, Alexander M.M. Eggermont, Caroline Robert, Sidong Huang, Anirudh Prahallad
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5b63cfde6924d5a39c6b040a57884b4
http://hdl.handle.net/2318/152041
http://hdl.handle.net/2318/152041
Autor:
Leticia G. Leon, Guus J. J. E. Heynen, René Bernards, Kwangho Lee, Elisa Giovannetti, Ravi S. Narayan, Elena Galvani, Rocco Sciarrillo, Robert Tjin Tham Sjin, Godefridus J. Peters, Kadoaki Ohashi, Jing Sun, William Pao, Roberta Alfieri, Daniëlle A.M. Heideman, Egbert F. Smit
Publikováno v:
Galvani, E, Sun, J, Leon, L G, Sciarrillo, R, Narayan, R S, Tjin Tham Sjin, R, Lee, K, Ohashi, K, Heideman, D A M, Alfieri, R R, Heynen, G J, Bernards, R, Smit, E F, Pao, W, Peters, G J & Giovannetti, E 2015, ' NF-kappaB drives acquired resistance to a novel mutant-selective EGFR inhibitor ', Oncotarget, vol. 6, no. 40, pp. 42717-42732 . https://doi.org/10.18632/oncotarget.3956
Oncotarget, 6(40), 42717. Impact Journals
Oncotarget
Oncotarget, 6(40), 42717-42732. Impact Journals
Oncotarget, 6(40), 42717. Impact Journals
Oncotarget
Oncotarget, 6(40), 42717-42732. Impact Journals
// Elena Galvani 1 , Jing Sun 2 , Leticia G. Leon 3 , Rocco Sciarrillo 1,4 , Ravi S. Narayan 5 , Robert Tjin Tham Sjin 6 , Kwangho Lee 6 , Kadoaki Ohashi 2 , Danielle A.M. Heideman 7 , Roberta R. Alfieri 8 , Guus J. Heynen 9 , Rene Bernards 9 , Egber